vimarsana.com

Latest Breaking News On - Moleculin biotech inc - Page 26 : vimarsana.com

Moleculin Biotech (NASDAQ:MBRX) Now Covered by StockNews com

Investment analysts at StockNews.com initiated coverage on shares of Moleculin Biotech (NASDAQ:MBRX – Get Rating) in a report released on Tuesday. The firm set a “sell” rating on the stock. MBRX has been the topic of a number of other reports. Oppenheimer reiterated an “outperform” rating and set a $5.00 target price on shares of […]

StockNews com Begins Coverage on Moleculin Biotech (NASDAQ:MBRX)

StockNews.com started coverage on shares of Moleculin Biotech (NASDAQ:MBRX – Get Rating) in a report released on Monday. The brokerage issued a sell rating on the stock. MBRX has been the topic of a number of other research reports. Oppenheimer reaffirmed an outperform rating and set a $5.00 price objective on shares of Moleculin Biotech […]

Moleculin Announces Adjournment of 2023 Annual Meeting to June 15, 2023

/PRNewswire/ Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a growing pipeline,.

Enzyme Trading 3% Lower Over Last 7 Days (MLN)

StockNews.com started coverage on shares of Moleculin Biotech (NASDAQ:MBRX – Get Rating) in a research report report published on Sunday. The brokerage issued a sell rating on the stock. MBRX has been the subject of a number of other reports. Roth Mkm reaffirmed a buy rating and set a $16.00 price target on shares of […]

Moleculin Biotech (NASDAQ:MBRX) Coverage Initiated at StockNews com

StockNews.com assumed coverage on shares of Moleculin Biotech (NASDAQ:MBRX – Get Rating) in a research report report published on Sunday morning. The firm issued a sell rating on the stock. A number of other brokerages also recently issued reports on MBRX. Roth Mkm reiterated a buy rating and issued a $16.00 price target on shares […]

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.